| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| QIA.DE - QIAGEN NV | BUY | 2,938 @ EUR 48.4172 | EUR 142,250 | The ETF bought 2938 new shares of QIA.DE (QIAGEN NV). The shares were bought for an average price of 48.4172 compared to the previous average buy price of 40.6149. This is 19.2% higher than average price of previous purchases of QIA.DE. |
| UCB.BR - UCB SA | BUY | 457 @ EUR 275.61 | EUR 125,954 | The ETF bought 457 new shares of UCB.BR (UCB SA). The shares were bought for an average price of 275.61 compared to the previous average buy price of 188.363. This is 46.3% higher than average price of previous purchases of UCB.BR. |
| GMAB.CO - | BUY | 376 @ DKK 318.436 | DKK 119,732 | The ETF bought 376 new shares of GMAB.CO (). The shares were bought for an average price of 318.436 compared to the previous average buy price of 214.002. This is 48.8% higher than average price of previous purchases of GMAB.CO. |
| GSK.L - GlaxoSmithKline PLC | BUY | 4,440 @ GBP 23.9947 | GBP 106,536 | The ETF bought 4440 new shares of GSK.L (GlaxoSmithKline PLC). The shares were bought for an average price of 23.9947 compared to the previous average buy price of 18.3574. This is 30.7% higher than average price of previous purchases of GSK.L. |
| NOVN.SW - | BUY | 795 @ CHF 130.702 | CHF 103,908 | The ETF bought 795 new shares of NOVN.SW (). The shares were bought for an average price of 130.702 compared to the previous average buy price of 105.855. This is 23.5% higher than average price of previous purchases of NOVN.SW. |
| 207940.KS - SAMSUNG BIOLOGICS LTD | BUY | 1 @ KRW 1126.42 | KRW 1,126 | The ETF bought 1 new shares of 207940.KS (SAMSUNG BIOLOGICS LTD). The shares were bought for an average price of 1126.42 compared to the previous average buy price of 720.393. This is 56.4% higher than average price of previous purchases of 207940.KS. |
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 14.3958 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 14.3958. The average price that 007390.KQ shares were previous bought at was KRW 21.5605. The current market price is -33.2% lower than average price they were purchased at. The value of the holding in 007390.KQ has fallen by KRW 8,760 (USD $6) compared to the previous valuation of NatureCell Co.,Ltd. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 40.0491 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 40.0491. The average price that 039200.KQ shares were previous bought at was KRW 20.0221. The current market price is 100.0% higher than average price they were purchased at. The value of the holding in 039200.KQ has increased by KRW 158,958 (USD $109) compared to the previous valuation of Oscotec Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 127.857 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 127.857. The average price that 068270.KS shares were previous bought at was KRW 121.344. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in 068270.KS has increased by KRW 490,283 (USD $335) compared to the previous valuation of CELLTRION INC however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 17.159 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 17.159. The average price that 096530.KQ shares were previous bought at was KRW 17.6796. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in 096530.KQ has increased by KRW 13,963 (USD $10) compared to the previous valuation of Seegene, Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.87727 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.87727. The average price that 13.HK shares were previous bought at was HKD 3.03049. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 8,165 (USD $1,050) compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 4.25514 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 3.23725 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 3.23725. The average price that 1877.HK shares were previous bought at was HKD 2.20212. The current market price is 47.0% higher than average price they were purchased at. The value of the holding in 1877.HK has increased by HKD 18,892 (USD $2,430) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 7.78458 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 7.78458. The average price that 2162.HK shares were previous bought at was HKD 5.23181. The current market price is 48.8% higher than average price they were purchased at. The value of the holding in 2162.HK has increased by HKD 54,665 (USD $7,031) compared to the previous valuation of KEYMED BIOSCIENCES INC however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 2.80528 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 2.80528. The average price that 2252.HK shares were previous bought at was HKD 3.78461. The current market price is -25.9% lower than average price they were purchased at. The value of the holding in 2252.HK has fallen by HKD 10,287 (USD $1,323) compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 70.6829 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 70.6829. The average price that 237690.KQ shares were previous bought at was KRW 54.2929. The current market price is 30.2% higher than average price they were purchased at. The value of the holding in 237690.KQ has increased by KRW 64,213 (USD $44) compared to the previous valuation of ST Pharm Co.,Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 118.305 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 118.305. The average price that 298380.KQ shares were previous bought at was KRW 40.1877. The current market price is 194.4% higher than average price they were purchased at. The value of the holding in 298380.KQ has increased by KRW 239,552 (USD $164) compared to the previous valuation of ABL Bio Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 35.9555 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 35.9555. The average price that 302440.KS shares were previous bought at was KRW 36.225. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in 302440.KS has increased by KRW 54,792 (USD $37) compared to the previous valuation of SK BIOSCIENCE LTD however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 95.9951 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 95.9951. The average price that 326030.KS shares were previous bought at was KRW 73.1926. The current market price is 31.2% higher than average price they were purchased at. The value of the holding in 326030.KS has increased by KRW 288,221 (USD $197) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 24.1523 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 24.1523. The average price that 328130.KQ shares were previous bought at was KRW 36.9599. The current market price is -34.7% lower than average price they were purchased at. The value of the holding in 328130.KQ has increased by KRW 15,846 (USD $11) compared to the previous valuation of Lunit Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.6392 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.6392. The average price that 3933.HK shares were previous bought at was HKD 1.74455. The current market price is -6.0% lower than average price they were purchased at. The value of the holding in 3933.HK has increased by HKD 20,935 (USD $2,692) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 32.1624 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 32.1624. The average price that 4523.T shares were previous bought at was JPY 28.0807. The current market price is 14.5% higher than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 1,544 (USD $10) compared to the previous valuation of Eisai Co., Ltd. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.867 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.867. The average price that 4549.T shares were previous bought at was JPY 13.6521. The current market price is 16.2% higher than average price they were purchased at. The value of the holding in 4549.T has increased by JPY 11,647 (USD $75) compared to the previous valuation of Eiken Chemical Co., Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.9318 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.9318. The average price that 4587.T shares were previous bought at was JPY 11.461. The current market price is -4.6% lower than average price they were purchased at. The value of the holding in 4587.T has increased by JPY 66,228 (USD $424) compared to the previous valuation of PeptiDream Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 12.3957 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 12.3957. The average price that 4887.T shares were previous bought at was JPY 13.3982. The current market price is -7.5% lower than average price they were purchased at. The value of the holding in 4887.T has increased by JPY 18,116 (USD $116) compared to the previous valuation of Sawai Group Holdings Co., Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.40834 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.40834. The average price that 4974.T shares were previous bought at was JPY 5.90785. The current market price is -8.5% lower than average price they were purchased at. The value of the holding in 4974.T has increased by JPY 5,456 (USD $35) compared to the previous valuation of Takara Bio Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.82899 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.82899. The average price that 6869.T shares were previous bought at was JPY 17.8798. The current market price is -45.0% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 125,594 (USD $804) compared to the previous valuation of Sysmex Corporation |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 30.4875 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 30.4875. The average price that 6951.T shares were previous bought at was JPY 33.4997. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in 6951.T has increased by JPY 29,974 (USD $192) compared to the previous valuation of JEOL Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 9.83858 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 9.83858. The average price that 7575.T shares were previous bought at was JPY 10.3645. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in 7575.T has increased by JPY 8,696 (USD $56) compared to the previous valuation of Japan Lifeline Co., Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 28.5376 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 28.5376. The average price that 7701.T shares were previous bought at was JPY 25.4348. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in 7701.T has fallen by JPY 17,571 (USD $112) compared to the previous valuation of Shimadzu Corporation |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 19.2105 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 19.2105. The average price that 7747.T shares were previous bought at was JPY 16.4838. The current market price is 16.5% higher than average price they were purchased at. The value of the holding in 7747.T has increased by JPY 152,221 (USD $974) compared to the previous valuation of Asahi Intecc Co., Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 10.9665 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 10.9665. The average price that 9995.HK shares were previous bought at was HKD 9.31045. The current market price is 17.8% higher than average price they were purchased at. The value of the holding in 9995.HK has increased by HKD 107,838 (USD $13,869) compared to the previous valuation of REMEGEN LTD H however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 154.37 | USD 0 | The current share valuation price of A based on adjusted close was USD 154.37. The average price that A shares were previous bought at was USD 118.65. The current market price is 30.1% higher than average price they were purchased at. The value of the holding in A has fallen by USD 348,752 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 227.66 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 227.66. The average price that ABBV shares were previous bought at was USD 191.211. The current market price is 19.1% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 324,452 compared to the previous valuation of AbbVie Inc |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.64 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.64. The average price that ABCL shares were previous bought at was USD 3.29477. The current market price is 10.5% higher than average price they were purchased at. The value of the holding in ABCL has increased by USD 5,143 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 128.54 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 128.54. The average price that ABT shares were previous bought at was USD 124.109. The current market price is 3.6% higher than average price they were purchased at. The value of the holding in ABT has increased by USD 54,249 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 24.81 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 24.81. The average price that ACAD shares were previous bought at was USD 17.44. The current market price is 42.3% higher than average price they were purchased at. The value of the holding in ACAD has increased by USD 62,345 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 73.25 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 73.25. The average price that ACLX shares were previous bought at was USD 63.8126. The current market price is 14.8% higher than average price they were purchased at. The value of the holding in ACLX has increased by USD 12,531 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 19.72 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 19.72. The average price that ADPT shares were previous bought at was USD 6.33052. The current market price is 211.5% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 111,165 compared to the previous valuation of Adaptive Biotechnologies Corp |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 29.72 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 29.72. The average price that ALKS shares were previous bought at was USD 31.5876. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in ALKS has increased by USD 144,616 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 344.57 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 344.57. The average price that AMGN shares were previous bought at was USD 287.725. The current market price is 19.8% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 175,114 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 15 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 15. The average price that AMLX shares were previous bought at was USD 11.84. The current market price is 26.7% higher than average price they were purchased at. The value of the holding in AMLX has increased by USD 10,790 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 42.16 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 42.16. The average price that ANAB shares were previous bought at was USD 22.9035. The current market price is 84.1% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 17,292 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.79998 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.79998. The average price that ARCT shares were previous bought at was USD 16.4363. The current market price is -58.6% lower than average price they were purchased at. USD 0 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 12.42 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 12.42. The average price that ARVN shares were previous bought at was USD 11.3332. The current market price is 9.6% higher than average price they were purchased at. The value of the holding in ARVN has increased by USD 25,726 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 23.05 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 23.05. The average price that ASTH shares were previous bought at was USD 27.1156. The current market price is -15.0% lower than average price they were purchased at. The value of the holding in ASTH has fallen by USD 8,354 compared to the previous valuation of Astrana Health Inc |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 36.03 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 36.03. The average price that ATRC shares were previous bought at was USD 33.1524. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in ATRC has fallen by USD 147,453 compared to the previous valuation of AtriCure Inc |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 16.37 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 16.37. The average price that AUPH shares were previous bought at was USD 8.80384. The current market price is 85.9% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 14,542 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| AXGN - Axogen Inc | HOLD | 0 @ USD 28.55 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 28.55. The average price that AXGN shares were previous bought at was USD 16.8496. The current market price is 69.4% higher than average price they were purchased at. The value of the holding in AXGN has increased by USD 12,316 compared to the previous valuation of Axogen Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 150.98 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 150.98. The average price that AXSM shares were previous bought at was USD 105.595. The current market price is 43.0% higher than average price they were purchased at. The value of the holding in AXSM has increased by USD 28,634 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BANB.SW - | HOLD | 0 @ CHF 63.2409 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 63.2409. The average price that BANB.SW shares were previous bought at was CHF 65.1273. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 15,961 (USD $19,754) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 29.1434 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 29.1434. The average price that BAVA.CO shares were previous bought at was DKK 24.9137. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 59,603 (USD $9,229) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.1 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.1. The average price that BCRX shares were previous bought at was USD 7.80196. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 62,543 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 25.03 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 25.03. The average price that BEAM shares were previous bought at was USD 17.8287. The current market price is 40.4% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 41,072 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 181.94 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 181.94. The average price that BIIB shares were previous bought at was USD 128.1. The current market price is 42.0% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 2,193 compared to the previous valuation of Biogen Inc |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 127.49 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 127.49. The average price that BIM.PA shares were previous bought at was EUR 119.434. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 44,726 (USD $51,725) compared to the previous valuation of BioMerieux however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 327.03 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 327.03. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 133,576 compared to the previous valuation of Bio-Rad Laboratories Inc |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 327.03 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 327.03. The average price that BIO shares were previous bought at was USD 280.042. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 133,576 compared to the previous valuation of Biotest Aktiengesellschaft |
| BIOA-B.ST - | HOLD | 0 @ SEK 32.0443 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 32.0443. The average price that BIOA-B.ST shares were previous bought at was SEK 23.3486. The current market price is 37.2% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has increased by SEK 74,849 (USD $7,855) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 26.68 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 26.68. The average price that BLFS shares were previous bought at was USD 26.74. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in BLFS has fallen by USD 17,704 compared to the previous valuation of BioLife Solutions Inc |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 49.25 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 49.25. The average price that BMY shares were previous bought at was USD 54.5268. The current market price is -9.7% lower than average price they were purchased at. The value of the holding in BMY has increased by USD 59,479 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 100.96 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.96. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 4.3% higher than average price they were purchased at. The value of the holding in BSX has fallen by USD 59,786 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 100.96 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.96. The average price that BSX shares were previous bought at was USD 96.7821. The current market price is 4.3% higher than average price they were purchased at. The value of the holding in BSX has fallen by USD 59,786 compared to the previous valuation of MULSTRXSSXIMETFP |
| CDNA - Caredx Inc | HOLD | 0 @ USD 17.81 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 17.81. The average price that CDNA shares were previous bought at was USD 19.5286. The current market price is -8.8% lower than average price they were purchased at. The value of the holding in CDNA has fallen by USD 5,641 compared to the previous valuation of Caredx Inc |
| CERT - Certara Inc | HOLD | 0 @ USD 9.14 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 9.14. The average price that CERT shares were previous bought at was USD 10.5583. The current market price is -13.4% lower than average price they were purchased at. The value of the holding in CERT has increased by USD 2,844 compared to the previous valuation of Certara Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 44.84 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 44.84. The average price that CGON shares were previous bought at was USD 33.16. The current market price is 35.2% higher than average price they were purchased at. The value of the holding in CGON has fallen by USD 49,294 compared to the previous valuation of CG Oncology, Inc. Common stock |
| CHEMM.CO - | HOLD | 0 @ DKK 120.267 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 120.267. The average price that CHEMM.CO shares were previous bought at was DKK 73.2155. The current market price is 64.3% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 22,796 (USD $3,530) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 23.43 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 23.43. The average price that CPRX shares were previous bought at was USD 22.1952. The current market price is 5.6% higher than average price they were purchased at. The value of the holding in CPRX has fallen by USD 23,444 compared to the previous valuation of Catalyst Pharmaceuticals Inc |
| CRL - Creightons Plc | HOLD | 0 @ USD 178.94 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 178.94. The average price that CRL shares were previous bought at was USD 161.828. The current market price is 10.6% higher than average price they were purchased at. The value of the holding in CRL has increased by USD 52,979 compared to the previous valuation of Creightons Plc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| CRVL - CorVel Corp | HOLD | 0 @ USD 73.29 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 73.29. The average price that CRVL shares were previous bought at was USD 112.167. The current market price is -34.7% lower than average price they were purchased at. The value of the holding in CRVL has fallen by USD 37,593 compared to the previous valuation of CorVel Corp |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 39.94 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 39.94. The average price that CSTL shares were previous bought at was USD 19.5501. The current market price is 104.3% higher than average price they were purchased at. The value of the holding in CSTL has increased by USD 352 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 5.6 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 5.6. The average price that CTKB shares were previous bought at was USD 5.75945. The current market price is -2.8% lower than average price they were purchased at. The value of the holding in CTKB has fallen by USD 35,196 compared to the previous valuation of Cytek Biosciences Inc |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.41 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.41. The average price that DAWN shares were previous bought at was USD 7.37. The current market price is 27.7% higher than average price they were purchased at. The value of the holding in DAWN has fallen by USD 1,859 compared to the previous valuation of Day One Biopharmaceuticals Inc |
| DHR - Danaher Corporation | HOLD | 0 @ USD 228.46 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 228.46. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 169,320 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 228.46 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 228.46. The average price that DHR shares were previous bought at was USD 197.976. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 169,320 compared to the previous valuation of Danaher Corporation |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 70.4672 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 70.4672. The average price that DIA.MI shares were previous bought at was EUR 51.5128. The current market price is 36.8% higher than average price they were purchased at. The value of the holding in DIA.MI has increased by EUR 17,027 (USD $19,691) compared to the previous valuation of DiaSorin SpA however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 11.43 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 11.43. The average price that DVAX shares were previous bought at was USD 12.9918. The current market price is -12.0% lower than average price they were purchased at. The value of the holding in DVAX has fallen by USD 5,768 compared to the previous valuation of Dynavax Technologies Corporation |
| DXCM - DexCom Inc | HOLD | 0 @ USD 62.53 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 62.53. The average price that DXCM shares were previous bought at was USD 79.7195. The current market price is -21.6% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 147,190 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| DYVOX.ST - | HOLD | 0 @ SEK 9.77845 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 9.77845. The average price that DYVOX.ST shares were previous bought at was SEK 6.01864. The current market price is 62.5% higher than average price they were purchased at. The value of the holding in DYVOX.ST has fallen by SEK 918 (USD $96) compared to the previous valuation of |
| EKTA-B.ST - | HOLD | 0 @ SEK 5.78606 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 5.78606. The average price that EKTA-B.ST shares were previous bought at was SEK 5.55917. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in EKTA-B.ST has increased by SEK 510,304 (USD $53,551) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| EMBC - Embecta Corp | HOLD | 0 @ USD 12.57 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 12.57. The average price that EMBC shares were previous bought at was USD 15.31. The current market price is -17.9% lower than average price they were purchased at. The value of the holding in EMBC has fallen by USD 70,855 compared to the previous valuation of Embecta Corp |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 18.6135 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 18.6135. The average price that EUZ.DE shares were previous bought at was EUR 20.0666. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in EUZ.DE has fallen by EUR 109 (USD $126) compared to the previous valuation of Eckert & Ziegler SE |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 4.2 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 4.2. The average price that EVH shares were previous bought at was USD 10.5742. The current market price is -60.3% lower than average price they were purchased at. The value of the holding in EVH has fallen by USD 14,203 compared to the previous valuation of Evolent Health Inc |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.61093 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.61093. The average price that EVT.DE shares were previous bought at was EUR 6.57563. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in EVT.DE has increased by EUR 43,875 (USD $50,741) compared to the previous valuation of Evotec SE however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 86.75 | USD 0 | The current share valuation price of EW based on adjusted close was USD 86.75. The average price that EW shares were previous bought at was USD 73.5436. The current market price is 18.0% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 13,714 compared to the previous valuation of Edwards Lifesciences Corp |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 101.45 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 101.45. The average price that EXAS shares were previous bought at was USD 51.941. The current market price is 95.3% higher than average price they were purchased at. The value of the holding in EXAS has increased by USD 72,971 compared to the previous valuation of EXACT Sciences Corporation however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 44.21 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 44.21. The average price that EXEL shares were previous bought at was USD 36.0106. The current market price is 22.8% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 355,845 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 12.63 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 12.63. The average price that FTRE shares were previous bought at was USD 10.2008. The current market price is 23.8% higher than average price they were purchased at. The value of the holding in FTRE has fallen by USD 16,898 compared to the previous valuation of Fortrea Holdings Inc. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 107.79 | USD 0 | The current share valuation price of GH based on adjusted close was USD 107.79. The average price that GH shares were previous bought at was USD 42.8441. The current market price is 151.6% higher than average price they were purchased at. The value of the holding in GH has fallen by USD 153,280 compared to the previous valuation of Guardant Health Inc |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 127.51 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 127.51. The average price that GILD shares were previous bought at was USD 102.696. The current market price is 24.2% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 52,607 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 30.8758 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 30.8758. The average price that GLPG.AS shares were previous bought at was EUR 28.0716. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in GLPG.AS has fallen by EUR 3,013 (USD $3,484) compared to the previous valuation of Galapagos NV |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 72.66 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 72.66. The average price that HALO shares were previous bought at was USD 58.3208. The current market price is 24.6% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 23,852 compared to the previous valuation of Halozyme Therapeutics Inc |
| HLUN-B.CO - | HOLD | 0 @ DKK 6.72253 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 6.72253. The average price that HLUN-B.CO shares were previous bought at was DKK 5.84339. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has increased by DKK 17,588 (USD $2,723) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.8 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.8. The average price that HOLX shares were previous bought at was USD 65.3166. The current market price is 14.5% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 18,237 compared to the previous valuation of Hologic Inc |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 35.56 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 35.56. The average price that HRMY shares were previous bought at was USD 32.4203. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in HRMY has increased by USD 11,791 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 13.12 | USD 0 | The current share valuation price of IART based on adjusted close was USD 13.12. The average price that IART shares were previous bought at was USD 21.5655. The current market price is -39.2% lower than average price they were purchased at. The value of the holding in IART has fallen by USD 10,651 compared to the previous valuation of Integra LifeSciences Holdings |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.13 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.13. The average price that IBRX shares were previous bought at was USD 2.8497. The current market price is -25.3% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 13,974 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 35.88 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 35.88. The average price that IDYA shares were previous bought at was USD 21.9973. The current market price is 63.1% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 41,034 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 129.81 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 129.81. The average price that ILMN shares were previous bought at was USD 92.7376. The current market price is 40.0% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 28,689 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.44 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.44. The average price that IOVA shares were previous bought at was USD 2.4224. The current market price is 0.7% higher than average price they were purchased at. The value of the holding in IOVA has fallen by USD 13,512 compared to the previous valuation of Iovance Biotherapeutics Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 144.875 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 144.875. The average price that IPN.PA shares were previous bought at was EUR 115.732. The current market price is 25.2% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 143,170 (USD $165,574) compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 231.8 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 231.8. The average price that IQV shares were previous bought at was USD 158. The current market price is 46.7% higher than average price they were purchased at. The value of the holding in IQV has fallen by USD 11,155 compared to the previous valuation of IQVIA Holdings Inc |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 574.23 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 574.23. The average price that ISRG shares were previous bought at was USD 526.895. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 130,282 compared to the previous valuation of Intuitive Surgical Inc |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 34.69 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 34.69. The average price that JANX shares were previous bought at was USD 25.3297. The current market price is 37.0% higher than average price they were purchased at. The value of the holding in JANX has fallen by USD 3,372 compared to the previous valuation of Janux Therapeutics Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 207.56 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 207.56. The average price that JNJ shares were previous bought at was USD 155.455. The current market price is 33.5% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 84,491 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 42.54 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 42.54. The average price that KNSA shares were previous bought at was USD 37.01. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in KNSA has fallen by USD 8,645 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 11.99 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 11.99. The average price that KURA shares were previous bought at was USD 8.825. The current market price is 35.9% higher than average price they were purchased at. The value of the holding in KURA has increased by USD 37,202 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.43 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.43. The average price that LAB shares were previous bought at was USD 1.33. The current market price is 7.5% higher than average price they were purchased at. The value of the holding in LAB has increased by USD 4,217 compared to the previous valuation of Standard Biotools Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 206.16 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 206.16. The average price that LGND shares were previous bought at was USD 112.221. The current market price is 83.7% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 61,175 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 63.84 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 63.84. The average price that LIVN shares were previous bought at was USD 41.8947. The current market price is 52.4% higher than average price they were purchased at. The value of the holding in LIVN has increased by USD 34,750 compared to the previous valuation of LivaNova PLC however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 58.75 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 58.75. The average price that LNTH shares were previous bought at was USD 85.3876. The current market price is -31.2% lower than average price they were purchased at. The value of the holding in LNTH has fallen by USD 25,790 compared to the previous valuation of Lantheus Holdings Inc |
| LONN.SW - | HOLD | 0 @ CHF 671.508 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 671.508. The average price that LONN.SW shares were previous bought at was CHF 624.949. The current market price is 7.5% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 96,416 (USD $119,330) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 105.02 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 105.02. The average price that MDT shares were previous bought at was USD 86.0044. The current market price is 22.1% higher than average price they were purchased at. The value of the holding in MDT has fallen by USD 55,745 compared to the previous valuation of Medtronic PLC |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 606.6 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 606.6. The average price that MEDP shares were previous bought at was USD 334.192. The current market price is 81.5% higher than average price they were purchased at. The value of the holding in MEDP has fallen by USD 151,163 compared to the previous valuation of Medpace Holdings Inc |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 86.22 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 86.22. The average price that MMS shares were previous bought at was USD 73.448. The current market price is 17.4% higher than average price they were purchased at. The value of the holding in MMS has fallen by USD 28,795 compared to the previous valuation of LYXETFETUSITETFP |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 104.63 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 104.63. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 31.3% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 188,036 compared to the previous valuation of Marks Electrical Group PLC |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 104.63 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 104.63. The average price that MRK shares were previous bought at was USD 79.7125. The current market price is 31.3% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 188,036 compared to the previous valuation of Merck & Company Inc |
| MRNA - Moderna Inc | HOLD | 0 @ USD 25.01 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 25.01. The average price that MRNA shares were previous bought at was USD 26.0014. The current market price is -3.8% lower than average price they were purchased at. The value of the holding in MRNA has increased by USD 121,649 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 96.09 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 96.09. The average price that MRUS shares were previous bought at was USD 52.0801. The current market price is 84.5% higher than average price they were purchased at. The value of the holding in MRUS has increased by USD 5,290 compared to the previous valuation of Merus BV however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.64 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.64. The average price that MRVI shares were previous bought at was USD 2.94723. The current market price is 23.5% higher than average price they were purchased at. The value of the holding in MRVI has fallen by USD 19,065 compared to the previous valuation of Maravai Lifesciences Holdings Inc |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 7.6 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 7.6. The average price that MYGN shares were previous bought at was USD 8.86565. The current market price is -14.3% lower than average price they were purchased at. The value of the holding in MYGN has fallen by USD 34,336 compared to the previous valuation of Myriad Genetics Inc |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 151.58 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 151.58. The average price that NBIX shares were previous bought at was USD 124.213. The current market price is 22.0% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 957,974 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 6.04 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 6.04. The average price that NEOG shares were previous bought at was USD 10.6516. The current market price is -43.3% lower than average price they were purchased at. The value of the holding in NEOG has increased by USD 10,482 compared to the previous valuation of Neogen Corporation however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 12.5122 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 12.5122. The average price that NEU.AX shares were previous bought at was AUD 6.49393. The current market price is 92.7% higher than average price they were purchased at. The value of the holding in NEU.AX has increased by AUD 78,393 (USD $50,723) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 237.12 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 237.12. The average price that NTRA shares were previous bought at was USD 159.203. The current market price is 48.9% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 56,613 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 8.01 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 8.01. The average price that NUVB shares were previous bought at was USD 3.35. The current market price is 139.1% higher than average price they were purchased at. The value of the holding in NUVB has increased by USD 38,539 compared to the previous valuation of Nuvation Bio Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.95 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.95. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 6.5% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 47,796 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.95 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.95. The average price that NVAX shares were previous bought at was USD 6.52576. The current market price is 6.5% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 47,796 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 12.76 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 12.76. The average price that NVCR shares were previous bought at was USD 23.2352. The current market price is -45.1% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 14,559 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.80952 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.80952. The average price that ONT.L shares were previous bought at was GBP 1.69938. The current market price is 6.5% higher than average price they were purchased at. The value of the holding in ONT.L has fallen by GBP 65,994 (USD $86,840) compared to the previous valuation of Oxford Nanopore Technologies Ltd |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 2.39 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 2.39. The average price that PACB shares were previous bought at was USD 1.30688. The current market price is 82.9% higher than average price they were purchased at. The value of the holding in PACB has fallen by USD 88,238 compared to the previous valuation of Pacific Biosciences of California |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.71 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.71. The average price that PFE shares were previous bought at was USD 24.2467. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 6,115 compared to the previous valuation of Pfizer Inc |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.75009 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.75009. The average price that PHARM.AS shares were previous bought at was EUR 0.824707. The current market price is 112.2% higher than average price they were purchased at. The value of the holding in PHARM.AS has increased by EUR 33,915 (USD $39,222) compared to the previous valuation of Pharming Group NV however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 89.8805 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 89.8805. The average price that PHM.MC shares were previous bought at was EUR 87.6333. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in PHM.MC has increased by EUR 12,145 (USD $14,045) compared to the previous valuation of Pharma Mar SA however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 170.197 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 170.197. The average price that PME.AX shares were previous bought at was AUD 163.975. The current market price is 3.8% higher than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 170,940 (USD $110,603) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 326.8 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 326.8. The average price that PODD shares were previous bought at was USD 275.459. The current market price is 18.6% higher than average price they were purchased at. The value of the holding in PODD has fallen by USD 101,902 compared to the previous valuation of Insulet Corporation |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 188.54 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 188.54. The average price that PRAX shares were previous bought at was USD 39.42. The current market price is 378.3% higher than average price they were purchased at. The value of the holding in PRAX has increased by USD 104,989 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 86.25 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 86.25. The average price that PTCT shares were previous bought at was USD 49.1674. The current market price is 75.4% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 316,223 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 27.5 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 27.5. The average price that QDEL shares were previous bought at was USD 29.6453. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in QDEL has fallen by USD 51,577 compared to the previous valuation of Quidel Corporation |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 25.56 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 25.56. The average price that RCUS shares were previous bought at was USD 8.69153. The current market price is 194.1% higher than average price they were purchased at. The value of the holding in RCUS has increased by USD 114,430 compared to the previous valuation of Arcus Biosciences Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 171.18 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 171.18. The average price that RGEN shares were previous bought at was USD 136.541. The current market price is 25.4% higher than average price they were purchased at. The value of the holding in RGEN has fallen by USD 36,749 compared to the previous valuation of Repligen Corporation |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 13.26 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 13.26. The average price that RGNX shares were previous bought at was USD 8.37881. The current market price is 58.3% higher than average price they were purchased at. The value of the holding in RGNX has fallen by USD 10,269 compared to the previous valuation of Regenxbio Inc |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.03 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.03. The average price that RLAY shares were previous bought at was USD 3.79905. The current market price is 111.4% higher than average price they were purchased at. The value of the holding in RLAY has fallen by USD 3,432 compared to the previous valuation of Relay Therapeutics Inc |
| RO.SW - | HOLD | 0 @ CHF 403.153 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 403.153. The average price that RO.SW shares were previous bought at was CHF 367.716. The current market price is 9.6% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 1,525 (USD $1,887) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 388.382 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 388.382. The average price that ROG.SW shares were previous bought at was CHF 304.279. The current market price is 27.6% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 8,285 (USD $10,254) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 104.66 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 104.66. The average price that RVTY shares were previous bought at was USD 87.5022. The current market price is 19.6% higher than average price they were purchased at. The value of the holding in RVTY has fallen by USD 129,584 compared to the previous valuation of Revvity Inc. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.41 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.41. The average price that RXRX shares were previous bought at was USD 5.16079. The current market price is -14.5% lower than average price they were purchased at. The value of the holding in RXRX has increased by USD 19,203 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 107.42 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 107.42. The average price that RYTM shares were previous bought at was USD 64.092. The current market price is 67.6% higher than average price they were purchased at. The value of the holding in RYTM has fallen by USD 93,836 compared to the previous valuation of Rhythm Pharmaceuticals Inc |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 17.42 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 17.42. The average price that SDGR shares were previous bought at was USD 23.4925. The current market price is -25.8% lower than average price they were purchased at. The value of the holding in SDGR has fallen by USD 2,113 compared to the previous valuation of Schrodinger Inc |
| SECT-B.ST - | HOLD | 0 @ SEK 30.319 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 30.319. The average price that SECT-B.ST shares were previous bought at was SEK 27.1554. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in SECT-B.ST has increased by SEK 20,074 (USD $2,107) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SFZN.SW - | HOLD | 0 @ CHF 89.1206 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 89.1206. The average price that SFZN.SW shares were previous bought at was CHF 124.687. The current market price is -28.5% lower than average price they were purchased at. The value of the holding in SFZN.SW has fallen by CHF 233 (USD $288) compared to the previous valuation of |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 17.29 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 17.29. The average price that SLP shares were previous bought at was USD 26.7306. The current market price is -35.3% lower than average price they were purchased at. The value of the holding in SLP has increased by USD 2,940 compared to the previous valuation of Sylvania Platinum Limited however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 20.95 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 20.95. The average price that SRPT shares were previous bought at was USD 57.6553. The current market price is -63.7% lower than average price they were purchased at. The value of the holding in SRPT has increased by USD 188,876 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 280.362 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 280.362. The average price that SRT3.DE shares were previous bought at was EUR 226.06. The current market price is 24.0% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 25,395 (USD $29,369) compared to the previous valuation of Sartorius AG |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 31.21 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 31.21. The average price that STOK shares were previous bought at was USD 11.6276. The current market price is 168.4% higher than average price they were purchased at. The value of the holding in STOK has increased by USD 91,113 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 46.26 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 46.26. The average price that SUPN shares were previous bought at was USD 34.9586. The current market price is 32.3% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 12,217 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SXS.L - Spectris PLC | HOLD | 0 @ GBP 54.6825 | GBP 0 | The current share valuation price of SXS.L based on adjusted close was GBP 54.6825. The average price that SXS.L shares were previous bought at was GBP 55.4271. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in SXS.L has increased by GBP 28,283 (USD $37,217) compared to the previous valuation of Spectris PLC however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 64.63 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 64.63. The average price that TECH shares were previous bought at was USD 58.2868. The current market price is 10.9% higher than average price they were purchased at. The value of the holding in TECH has fallen by USD 231,658 compared to the previous valuation of Bio-Techne Corp |
| TECN.SW - | HOLD | 0 @ CHF 172.407 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 172.407. The average price that TECN.SW shares were previous bought at was CHF 202.814. The current market price is -15.0% lower than average price they were purchased at. The value of the holding in TECN.SW has fallen by CHF 8,137 (USD $10,071) compared to the previous valuation of |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 33.41 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 33.41. The average price that TGTX shares were previous bought at was USD 34.3438. The current market price is -2.7% lower than average price they were purchased at. The value of the holding in TGTX has increased by USD 74,156 compared to the previous valuation of TG Therapeutics Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 593.25 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 593.25. The average price that TMO shares were previous bought at was USD 407.896. The current market price is 45.4% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 162,314 compared to the previous valuation of Time Out Group plc |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 20.73 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 20.73. The average price that TNDM shares were previous bought at was USD 22.0991. The current market price is -6.2% lower than average price they were purchased at. The value of the holding in TNDM has fallen by USD 88,322 compared to the previous valuation of Tandem Diabetes Care Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 31.7 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 31.7. The average price that TWST shares were previous bought at was USD 42.9063. The current market price is -26.1% lower than average price they were purchased at. The value of the holding in TWST has increased by USD 38,901 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 18.75 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 18.75. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 56.6% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 42,698 compared to the previous valuation of 10X Genomics Inc |
| TXG - Terex Corporation | HOLD | 0 @ USD 18.75 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 18.75. The average price that TXG shares were previous bought at was USD 11.9745. The current market price is 56.6% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 42,698 compared to the previous valuation of Terex Corporation |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 47.71 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 47.71. The average price that VCYT shares were previous bought at was USD 31.3293. The current market price is 52.3% higher than average price they were purchased at. The value of the holding in VCYT has fallen by USD 149,742 compared to the previous valuation of Veracyte Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 6.39 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.39. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -20.5% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 6,188 compared to the previous valuation of Vir Biotechnology Inc |
| VIR - Vidrala S.A | HOLD | 0 @ USD 6.39 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.39. The average price that VIR shares were previous bought at was USD 8.03707. The current market price is -20.5% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 6,188 compared to the previous valuation of Vidrala S.A |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.72409 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.72409. The average price that VLA.PA shares were previous bought at was EUR 2.86092. The current market price is 65.1% higher than average price they were purchased at. The value of the holding in VLA.PA has increased by EUR 57,367 (USD $66,344) compared to the previous valuation of Valneva SE however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 5.3 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 5.3. The average price that VNDA shares were previous bought at was USD 4.49047. The current market price is 18.0% higher than average price they were purchased at. The value of the holding in VNDA has increased by USD 20,541 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 31.72 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 31.72. The average price that VRDN shares were previous bought at was USD 19.65. The current market price is 61.4% higher than average price they were purchased at. The value of the holding in VRDN has increased by USD 30,663 compared to the previous valuation of Viridian Therapeutics Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| XVIVO.ST - | HOLD | 0 @ SEK 18.8626 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 18.8626. The average price that XVIVO.ST shares were previous bought at was SEK 42.7002. The current market price is -55.8% lower than average price they were purchased at. The value of the holding in XVIVO.ST has fallen by SEK 17,736 (USD $1,861) compared to the previous valuation of |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 27.33 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 27.33. The average price that ZYME shares were previous bought at was USD 14.3. The current market price is 91.1% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 71,552 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |